论文部分内容阅读
目的 分析单纯 11三体异常与恶性血液病的临床、血液学、免疫学及预后的关系。方法 对所有病例采用骨髓细胞直接法或短期培养法制备染色体标本 ,采用R显带技术进行核型分析。对 5例患者作了白血病细胞表面免疫标记分析 ,10例急性髓系白血病 (AML)患者接受HA(高三尖杉酯碱、阿糖胞苷 )为主的方案治疗 ,并随访治疗结果和生存期。结果 在 176 3例恶性髓系血液病患者中发现 11例有单纯 11三体异常 ,发生率为 0 .6 %。疾病类型为AML 10例 (M2 6例 ,M52例 ,M1 和M4 各 1例 ) ,骨髓增生异常综合征 1例。 10例患者均无肝、脾肿大 (1例资料不详 )。 5例白血病细胞免疫标志检测显示CD34 (+)、CD1 3(+)和CD33(+)。随访的 10例患者总缓解率为 4 0 % ,中位生存期为 10个月。结论 单纯 11三体异常主要见于急性髓系白血病 ,以M2 最多见 ,其预后不良。
Objective To analyze the relationship between clinical manifestations, hematology, immunology and prognosis of simple 11 trisomy and hematologic malignancies. Methods Chromosomal specimens were prepared by direct method or short-term culture of bone marrow cells in all cases. Karyotyping was performed by R-banding technique. Immunofluorescent labeling of leukemic cells was performed in 5 patients. 10 patients with acute myeloid leukemia (AML) were treated with HA (homoharringtonine and cytarabine), and were followed up for the treatment outcome and survival . Results Of 176 patients with malignant myeloid hematopathy, 11 patients had a simple 11 trisomy with a incidence of 0.6%. The disease type AML 10 cases (M2 6 cases, M52 cases, M1 and M4 1), myelodysplastic syndrome in 1 case. None of the 10 patients had liver and splenomegaly (one case was unknown). Five leukemia cell immunodetection markers showed CD34 (+), CD13 (+) and CD33 (+). The follow-up of 10 patients, the total remission rate was 40%, the median survival was 10 months. Conclusions The simple trisomy 11 is mainly found in acute myeloid leukemia, the most common is M2, and its prognosis is poor.